Efavirenz in an obese HIV-infected patient--a report and an in vitro-in vivo extrapolation model indicate risk of underdosing.
Here, we report suboptimal efavirenz exposure in an obese patient treated with the standard 600 mg dose. Tripling the dose allowed attainment of therapeutic efavirenz concentrations. We developed an in vitro-in vivo extrapolation model to quantify dose requirements in obese individuals. Obesity represents a risk factor for antiretroviral therapy underdosing.
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
Mirjam
M
de Roche
Marco
M
Siccardi
Marcel
M
Stoeckle
Françoise
F
Livio
David
D
Back
Manuel
M
Battegay
Catia
C
Marzolini
D000480:Alkynes; D048588:Benzoxazines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D015992:Body Mass Index; D003198:Computer Simulation; D003521:Cyclopropanes; D054796:Drug Dosage Calculations; D016903:Drug Monitoring / Q000379:methods; D006678:HIV / Q000472:pathogenicity; D015658:HIV Infections / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000473:pathology*; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics; D012307:Risk Factors; D019562:Viral Load
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz